TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
Delayed Japan Exchange  -  02:00 2022-06-27 am EDT
3776.00 JPY   +1.86%
06:02aResults from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
BU
06/24Takeda Pharmaceutical to Absorb Businesses From Unit Nihon Pharmaceutical
MT
06/22Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical's FY22 Attributable Profit Falls 39%

05/11/2022 | 11:37pm EDT


© MT Newswires 2022
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
06:02aResults from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficienc..
BU
06/24Takeda Pharmaceutical to Absorb Businesses From Unit Nihon Pharmaceutical
MT
06/22Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation..
BU
06/22Takeda Signs 15-Year Lease with BioMed Realty
CI
06/17MARKETSCREENER'S WORLD PRESS REVIEW : June 17, 2022
06/17Takeda, Nintendo among Japanese firms quietly celebrating weak yen
RE
06/10Takeda's Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Th..
AQ
06/10TAKEDA PHARMACEUTICAL : Notice Concerning Disposal of Treasury Shares under the Long-Term ..
PU
06/09Takeda Pharmaceutical Says Dengue Vaccine Candidate 84% Effective Against Hospitalizati..
MT
06/09Takeda's Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Th..
BU
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 490 B 25 833 M 25 833 M
Net income 2022 239 B 1 768 M 1 768 M
Net Debt 2022 3 299 B 24 416 M 24 416 M
P/E ratio 2022 24,2x
Yield 2022 4,86%
Capitalization 5 722 B 42 353 M 42 353 M
EV / Sales 2022 2,58x
EV / Sales 2023 2,32x
Nbr of Employees 47 099
Free-Float 96,8%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 3 707,00 JPY
Average target price 4 468,13 JPY
Spread / Average Target 20,5%
EPS Revisions
Managers and Directors
Christophe Weber Chief Operating & Corporate Officer
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED18.17%42 353
JOHNSON & JOHNSON6.56%479 678
ELI LILLY AND COMPANY17.88%293 110
PFIZER, INC.-12.63%289 466
ROCHE HOLDING AG-15.91%272 090
ABBVIE INC.12.51%269 202